AQR Capital Management’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $134K | Buy |
+42,192
| New | +$165K | ﹤0.01% | 3663 |
|
|
2024
Q4 | – | Sell |
-389
| Closed | -$4.31K | – | 2974 |
|
|
2024
Q3 | $4.31K | Sell |
389
-528
| -58% | -$6.19K | ﹤0.01% | 2750 |
|
|
2024
Q2 | $8.52K | Buy |
917
+116
| +14% | +$2.77K | ﹤0.01% | 2591 |
|
|
2024
Q1 | $26.2K | Sell |
801
-22,221
| -97% | -$576K | ﹤0.01% | 2389 |
|
|
2023
Q4 | $616K | Buy |
23,022
+5,053
| +28% | +$209K | ﹤0.01% | 1798 |
|
|
2023
Q3 | $1.09M | Buy |
+17,969
| New | +$1.69M | ﹤0.01% | 1573 |
|
|
2022
Q3 | – | Sell |
-485
| Closed | -$160K | – | 2345 |
|
|
2022
Q2 | $160K | Sell |
485
-708
| -59% | -$248K | ﹤0.01% | 2022 |
|
|
2022
Q1 | $522K | Sell |
1,193
-2,088
| -64% | -$857K | ﹤0.01% | 1806 |
|
|
2021
Q4 | $1.44M | Buy |
3,281
+2,493
| +316% | +$1.25M | ﹤0.01% | 1372 |
|
|
2021
Q3 | $438K | Sell |
788
-503
| -39% | -$252K | ﹤0.01% | 1908 |
|
|
2021
Q2 | $663K | Buy |
1,291
+1,013
| +364% | +$642K | ﹤0.01% | 1784 |
|
|
2021
Q1 | $218K | Buy |
+278
| New | +$190K | ﹤0.01% | 2094 |
|
|
2020
Q1 | – | Sell |
-390
| Closed | -$226K | – | 2170 |
|
|
2019
Q4 | $226K | Sell |
390
-22
| -5% | -$15.4K | ﹤0.01% | 1981 |
|
|
2019
Q3 | $271K | Buy |
412
+114
| +38% | +$94.8K | ﹤0.01% | 1937 |
|
|
2019
Q2 | $231K | Buy |
+298
| New | +$209K | ﹤0.01% | 1943 |
|
|
2019
Q1 | – | Sell |
-293
| Closed | -$137K | – | 2231 |
|
|
2018
Q4 | $137K | Buy |
+293
| New | +$189K | ﹤0.01% | 2123 |
|
|
2018
Q2 | – | Sell |
-467
| Closed | -$208K | – | 2395 |
|
|
2018
Q1 | $208K | Sell |
467
-403
| -46% | -$195K | ﹤0.01% | 2135 |
|
|
2017
Q4 | $383K | Sell |
870
-340
| -28% | -$155K | ﹤0.01% | 1999 |
|
|
2017
Q3 | $596K | Sell |
1,210
-98
| -7% | -$49.1K | ﹤0.01% | 1877 |
|
|
2017
Q2 | $725K | Buy |
1,308
+771
| +144% | +$489K | ﹤0.01% | 1773 |
|
|
2017
Q1 | $355K | Buy |
+537
| New | +$287K | ﹤0.01% | 1978 |
|
|
2016
Q4 | – | Sell |
-1,163
| Closed | -$349K | – | 2289 |
|
|
2016
Q3 | $349K | Sell |
1,163
-3,200
| -73% | -$693K | ﹤0.01% | 2043 |
|
|
2016
Q2 | $755K | Buy |
4,363
+883
| +25% | +$192K | ﹤0.01% | 1714 |
|
|
2016
Q1 | $779K | Buy |
3,480
+385
| +12% | +$115K | ﹤0.01% | 1676 |
|
|
2015
Q4 | $1.88M | Buy |
3,095
+981
| +46% | +$539K | ﹤0.01% | 1276 |
|
|
2015
Q3 | $1.09M | Buy |
2,114
+1,663
| +369% | +$1.11M | ﹤0.01% | 1384 |
|
|
2015
Q2 | $197K | Buy |
+451
| New | +$174K | ﹤0.01% | 2115 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
AQR Capital Management's TVRD Position: Q1 2026 in Review
AQR Capital Management opened a new position in Tvardi Therapeutics (TVRD) in Q1 2026: 42,192 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #3663 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in TVRD as recently as Q3 2024.
AQR Capital Management first reported a position in TVRD in Q2 2015 and has held it in 27 quarters since. The position peaked at $1.88M in Q4 2015. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- AQR Capital Management held 42,192 shares of Tvardi Therapeutics worth $134K as of Q1 2026.
- Tvardi Therapeutics was a new AQR Capital Management position in Q1 2026.
- Tvardi Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3663 holding.
- AQR Capital Management first reported a position in Tvardi Therapeutics in Q2 2015 and has held it in 27 quarters since.
- AQR Capital Management's Tvardi Therapeutics position peaked at $1.88M in Q4 2015.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.